Update: 28.03.2021
Last week: 11 week 2022 (14.03.2022 - 20.03.2022)
Last full month: Feb 2022
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | |||||||||
| WoW | 3 243 | -4.4% | 59.2% | -2.8 | 1 602 546 | -9.6% | 85.0% | -2.4 | 0.2% |
| MoM | 11 577 | 16.9% | 55.7% | 4.2 | 5 204 099 | 19.8% | 82.7% | 2.8 | 8.1% |
| YTD | 30 900 | 9.8% | 55.7% | -3.5 | 14 229 726 | 41.2% | 82.9% | 1.1 | 16.7% |
| MAT | 120 372 | -19.6% | 54.8% | -6.8 | 49 759 594 | 6.9% | 80.6% | -0.7 | -9.6% |
| KAPSIKAM | |||||||||
| WoW | 27 355 | 12.3% | 3.5% | 0.4 | 12 139 146 | 15.0% | 3.4% | 0.5 | -0.5% |
| MoM | 184 740 | -6.2% | 3.7% | -0.2 | 75 707 986 | -6.3% | 3.8% | -0.3 | -1.2% |
| YTD | 260 280 | -5.0% | 3.6% | -0.2 | 108 602 262 | -5.8% | 3.6% | -0.9 | 0.3% |
| MAT | 1 051 339 | -19.1% | 3.3% | -0.4 | 432 232 523 | -11.9% | 3.5% | -0.6 | -9.4% |
| MILDRONATE | |||||||||
| WoW | 157 226 | -4.0% | 22.3% | -0.3 | 106 679 013 | 6.0% | 23.5% | 0.5 | -2.7% |
| MoM | 508 991 | 18.0% | 21.8% | 1 | 242 664 826 | 38.3% | 20.6% | 2.7 | 12.6% |
| YTD | 1 413 911 | 33.4% | 16.8% | 2.2 | 718 235 084 | 59.4% | 17.1% | 3.1 | 16.0% |
| MAT | 5 149 870 | 14.0% | 17.0% | 2.7 | 2 201 114 512 | 22.6% | 15.5% | 2.4 | -4.1% |
| SULFARGIN | |||||||||
| WoW | 3 359 | -17.7% | 0.6% | -0.1 | 1 701 817 | -18.0% | 0.7% | -0.2 | -4.9% |
| MoM | 14 059 | 2.0% | 1.0% | 0 | 6 756 585 | 0.2% | 1.3% | 0 | 2.0% |
| YTD | 37 848 | 9.6% | 0.9% | 0.1 | 18 576 389 | 14.9% | 1.1% | 0.1 | -3.1% |
| MAT | 167 464 | -18.0% | 0.8% | -0.1 | 82 165 275 | -6.6% | 1.2% | 0 | -8.3% |
| VIPROSAL | |||||||||
| WoW | 36 336 | 1.0% | 4.3% | 0 | 15 861 504 | 1.7% | 4.1% | 0.1 | 1.0% |
| MoM | 122 479 | 0.5% | 4.5% | 0.1 | 48 514 619 | 1.0% | 4.5% | 0 | -1.7% |
| YTD | 347 065 | 41.2% | 4.4% | 1.2 | 141 154 281 | 48.9% | 4.3% | 0.9 | 2.7% |
| MAT | 1 344 800 | -1.6% | 4.0% | 0.3 | 517 637 097 | 6.0% | 4.0% | 0.1 | -9.0% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 3 243 | -4.4% | 59.2% | -2.8 | 1 602 546 | -9.6% | 85.0% | -2.4 | 0.2% |
| KAPSIKAM | 27 355 | 12.3% | 3.5% | 0.4 | 12 139 146 | 15.0% | 3.4% | 0.5 | -0.5% |
| MILDRONATE | 157 226 | -4.0% | 22.3% | -0.3 | 106 679 013 | 6.0% | 23.5% | 0.5 | -2.7% |
| SULFARGIN | 3 359 | -17.7% | 0.6% | -0.1 | 1 701 817 | -18.0% | 0.7% | -0.2 | -4.9% |
| VIPROSAL | 36 336 | 1.0% | 4.3% | 0 | 15 861 504 | 1.7% | 4.1% | 0.1 | 1.0% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 11 577 | 16.9% | 55.7% | 4.2 | 5 204 099 | 19.8% | 82.7% | 2.8 | 8.1% |
| KAPSIKAM | 184 740 | -6.2% | 3.7% | -0.2 | 75 707 986 | -6.3% | 3.8% | -0.3 | -1.2% |
| MILDRONATE | 508 991 | 18.0% | 21.8% | 1 | 242 664 826 | 38.3% | 20.6% | 2.7 | 12.6% |
| SULFARGIN | 14 059 | 2.0% | 1.0% | 0 | 6 756 585 | 0.2% | 1.3% | 0 | 2.0% |
| VIPROSAL | 122 479 | 0.5% | 4.5% | 0.1 | 48 514 619 | 1.0% | 4.5% | 0 | -1.7% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 30 900 | 9.8% | 55.7% | -3.5 | 14 229 726 | 41.2% | 82.9% | 1.1 | 16.7% |
| KAPSIKAM | 260 280 | -5.0% | 3.6% | -0.2 | 108 602 262 | -5.8% | 3.6% | -0.9 | 0.3% |
| MILDRONATE | 1 413 911 | 33.4% | 16.8% | 2.2 | 718 235 084 | 59.4% | 17.1% | 3.1 | 16.0% |
| SULFARGIN | 37 848 | 9.6% | 0.9% | 0.1 | 18 576 389 | 14.9% | 1.1% | 0.1 | -3.1% |
| VIPROSAL | 347 065 | 41.2% | 4.4% | 1.2 | 141 154 281 | 48.9% | 4.3% | 0.9 | 2.7% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 120 372 | -19.6% | 54.8% | -6.8 | 49 759 594 | 6.9% | 80.6% | -0.7 | -9.6% |
| KAPSIKAM | 1 051 339 | -19.1% | 3.3% | -0.4 | 432 232 523 | -11.9% | 3.5% | -0.6 | -9.4% |
| MILDRONATE | 5 149 870 | 14.0% | 17.0% | 2.7 | 2 201 114 512 | 22.6% | 15.5% | 2.4 | -4.1% |
| SULFARGIN | 167 464 | -18.0% | 0.8% | -0.1 | 82 165 275 | -6.6% | 1.2% | 0 | -8.3% |
| VIPROSAL | 1 344 800 | -1.6% | 4.0% | 0.3 | 517 637 097 | 6.0% | 4.0% | 0.1 | -9.0% |
## [1] "VIPROSAL"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"
## [1] "VIPROSAL"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"
## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"
## [1] "KAPSIKAM"
## [1] "KAPSIKAM UNGUENT FOR EXT USE 30 G #1"
## [1] "KAPSIKAM UNGUENT FOR EXT USE 50 G #1"
## [1] "KAPSIKAM"
## [1] "KAPSIKAM UNGUENT FOR EXT USE 30 G #1"
## [1] "KAPSIKAM UNGUENT FOR EXT USE 50 G #1"
## [1] "MILDRONATE"
## [1] "MILDRONATE CAPS 250 MG #20"
## [1] "MILDRONATE CAPS 250 MG #40"
## [1] "MILDRONATE CAPS 500 MG #30"
## [1] "MILDRONATE CAPS 500 MG #60"
## [1] "MILDRONATE CAPS 500 MG #90"
## [1] "MILDRONATE"
## [1] "MILDRONATE CAPS 250 MG #20"
## [1] "MILDRONATE CAPS 250 MG #40"
## [1] "MILDRONATE CAPS 500 MG #30"
## [1] "MILDRONATE CAPS 500 MG #60"
## [1] "MILDRONATE CAPS 500 MG #90"
## [1] "SULFARGIN"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"
## [1] "SULFARGIN"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"
## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"
## [1] "APILAC"
## [1] "APILAC TABS 10 MG #25"
## [1] "APILAC TABS 10 MG #50"
## [1] "APILAC"
## [1] "APILAC TABS 10 MG #25"
## [1] "APILAC TABS 10 MG #50"
Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs